CO1686 - 3rd Generation Drug for Acquired Resistance in EGFR Lung Cancer

GRACEcast by Howard (Jack) West, MD

Lung cancer patients with the EGFR mutation who had progressed on other drugs did well on a new drug in clinical trial, though one particular side effect concerns some.